MDS

NKG2D CARs for R/R AML and MDS

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS

Hypomethylating agents for low risk MDS

IDH inhibitors for AML and MDS

Computational methods are the future of biological research

A new set of treatment options for low-risk MDS

Highlights: ASCO 2018 oral abstract presentations

A worldwide Phase III trial treating AML with pracinostat

Targeting DNA methylation as a therapeutic target in multiple myeloma

The future of AML and MDS diagnosis and treatment

The molecular mechanisms of epigenetic therapies: LTRs and TINATs

Therapeutics targeting splicing in hematological malignancies

The drugs being used to treat newly diagnosed AML patients

Bispecific agents: the future of AML and MDS treatment?

HARMONY: a collaboration between 51 partners

Using computational algorithms to predict the response of MDS patients to hypomethylating agents